Paullinia tomentosa

Paullinia tomentosa

Nomenclature, Taxonomic Identity, and Botanical Overview

Paullinia tomentosa Jacq. is a species of flowering liana (woody vine) in the family Sapindaceae, described by the Austrian botanist Nikolaus Joseph von Jacquin in his 1760 work Enumeratio Systematica Plantarum. According to the GBIF Backbone Taxonomy, it belongs to the kingdom Plantae, phylum Tracheophyta, class Magnoliopsida, order Sapindales, and family Sapindaceae, within the genus Paullinia. Paullinia tomentosa is a species of eudicot in the family Sapindaceae.

The species carries the homonym designation Paullinia tomentosa Jacq. and is known by the common Spanish name barbasco flor. Recognized synonyms in the botanical literature include Paullinia brevispica E.Fourn. and Paullinia brevispica E.Fourn. ex Radlk., as well as Paullinia pteropoda Moc. & Sessé and Paullinia pteropoda Moc. & Sessé ex DC. Herbarium specimens of the species have been collected from Mexico, confirming its presence in Mesoamerica in addition to the wider Caribbean and South American range implied by its original description.

It is essential at the outset to note that Paullinia tomentosa Jacq. is a taxonomically distinct species and must not be confused with two other organisms that share a similar phonetic name but belong to entirely different plant families and continents:

• Paulownia tomentosa (Thunb.) Steud. — a deciduous hardwood tree in the family Paulowniaceae, native to central and eastern China and the Korean Peninsula, commonly known as the princess tree or empress tree. It is entirely unrelated to the genus Paullinia.
• Uncaria tomentosa (Willd. ex Schult.) DC. — a Rubiaceae vine from the Peruvian Amazon, widely known as cat's claw, also unrelated to Paullinia.

These distinctions are taxonomically absolute and are critical for accurate interpretation of any literature or product label referencing these names.

The Genus Paullinia: Systematic Context

Paullinia L. (Paullinieae: Sapindaceae) is a genus of approximately 220 lianas native to the Neotropics, with one species ranging from tropical sub-Saharan Africa to Zimbabwe. The Amazon region is the center of diversity of the genus, containing 44% of the described species.

Members of Paullinia can be identified based on their habit as lianas or vines — seldom erect shrubs — their alternate compound leaves with a terminal leaflet, and their septifragal capsular fruits enclosing arillate seeds.

In addition to its taxonomic diversity and morphological disparity, the genus has an extensive history of human utilization. Almost 20% of Paullinia species are reported to have ethnobotanical uses by the indigenous peoples of Central and South America, primarily as fish poisons, medicines, and caffeine-rich stimulants. The greatest economic impact, however, is from the caffeine-rich seeds of P. cupana Kunth, known colloquially as guaraná, which is an important international export commodity for Brazil.

Phytochemistry of the Genus and the Specific Position of P. tomentosa

Because species-specific pharmacological literature on Paullinia tomentosa Jacq. is currently absent from peer-reviewed databases, the phytochemical context of this species must be drawn primarily from genus-level investigations and from what is scientifically established for the most closely studied congeners.

Purine Alkaloid Distribution Across the Genus

A central question regarding the phytochemistry of P. tomentosa as a putative stimulant ingredient is whether it contains caffeine or other purine alkaloids. A systematic peer-reviewed chemotaxonomic screening of 34 Paullinia species provides the most authoritative available answer. Among the few purine alkaloid-containing genera consumed as stimulants, Paullinia is the least investigated with respect to both chemotaxonomy and within-the-plant allocation of caffeine and its allies. When 34 species of Paullinia and related genera were screened for purine alkaloids (PuA), only one — P. pachycarpa — was positive in addition to the already known P. cupana and P. yoco. Paullinia tomentosa was among the species screened and was not found to be positive for purine alkaloids in this study (Weckerle et al., Phytochemistry, 2003, PMID 13679096). This finding directly challenges commercially disseminated claims that P. tomentosa is a caffeine-rich stimulant analogous to guarana, which are not supported by this peer-reviewed evidence.

The PuA allocation in P. pachycarpa was found to be restricted to theobromine in the stem, leaves, and flowers, with theobromine concentration in the stem cortex increasing significantly towards the base of the plant. The stem cortex of P. yoco is traditionally used by the natives of Colombia and Ecuador to prepare a caffeine-rich beverage, suggesting that within the genus Paullinia the PuA are preferentially allocated to the older parts of the stem.

General Phytochemistry of Related Paullinia Species

The phytochemical profile of Paullinia cupana — the closest well-studied congener to P. tomentosa — provides a point of chemical comparison for the genus, though extrapolation to P. tomentosa is not scientifically justified without species-specific data. Guarana is derived from the seeds of Paullinia cupana, which is native to the Amazon Basin. The seeds contain a high concentration of caffeine (2% to 8%), far higher than in coffee beans (1% to 3%). The seeds are also rich in other xanthine alkaloids such as theophylline and theobromine, as well as catechins, epicatechins, and procyanidins.

For the African liana Paullinia pinnata, another congener with its own body of study, phytochemical studies have revealed the presence of phenols, flavonoids, triterpene, saponins and tannins, steroids, steroidal glycosides, and cerebroside and ceramide, with isolated compounds including 2-O-methyl-L-chiro-inositol, β-sitosterol, and friedelin. These findings illustrate that Paullinia species as a group contain diverse secondary metabolites, but the profile varies considerably between species.

Traditional and Historical Use

The Genus in Indigenous Practice

The genus Paullinia has an extensive history of human utilization. Almost 20% of Paullinia species are reported to have ethnobotanical uses by the indigenous peoples of Central and South America, primarily as fish poisons, medicines, and caffeine-rich stimulants.

For species closely related to P. tomentosa, specific traditional uses are documented at the species level. For example, P. pinnata, distributed across parts of South America and Africa, has documented uses as a fish poison — the long flexible stems of P. pinnata are used to poison fish in shallow pools, as described by the English naturalist Henry Walter Bates in his book The Naturalist on the River Amazons. In Cameroon, P. pinnata leaf decoction is used for the treatment of bacterial infections including typhoid fever, syphilis, gonorrhea, diarrhea, and symptoms such as stomach-ache and waist pain.

For P. yoco, the stem cortex is traditionally used by the natives of Colombia and Ecuador to prepare a caffeine-rich beverage. P. cupana (guarana) holds the most thoroughly documented traditional use within the genus: guarana is an extract of roasted and pulverized seeds of Paullinia cupana, indigenous to the Amazon Basin, whose major active components are caffeine and other xanthine alkaloids such as theophylline and theobromine. Guarana has been used as a stimulant and tonic to treat fatigue, decrease hunger and thirst, and for headaches and dysmenorrhea.

Attributed Traditional Uses of P. tomentosa Specifically

A single, non-peer-reviewed commercial ingredient database (caringsunshine.com) attributes to Paullinia tomentosa traditional uses including energy promotion, fatigue reduction, and alertness enhancement among Amazonian indigenous communities, claiming preparations including decoctions, infusions, and tonics from seeds, leaves, and bark. These claims cannot be verified against peer-reviewed ethnobotanical literature, government monographs, WHO or ESCOP documentation, or any other qualifying authoritative source identified in literature searches. No ethnopharmacological surveys, pharmacognostic monographs, or academic ethnobotanical studies specifically documenting the traditional use of Paullinia tomentosa Jacq. as a distinct species were identified in peer-reviewed databases including PubMed/PMC. These claims are therefore presented here solely as commercially attributed assertions, not as verified historical or ethnobotanical facts.

Scientific Evidence: Current State of Research

Species-Specific Evidence for Paullinia tomentosa

A thorough search of PubMed/NCBI, PMC, and academic literature databases returns no peer-reviewed pharmacological, toxicological, or clinical studies specifically investigating Paullinia tomentosa Jacq. as a distinct subject of research. The NCBI Taxonomy database confirms Paullinia tomentosa as a valid taxonomic entry (Taxonomy ID: 1823681), but no associated studies appear in the NCBI literature databases under this species name.

Scientific investigation into P. tomentosa is still in the early stages, as even the sole commercial reference acknowledges. Direct clinical studies in humans remain limited, which — given the total absence of any published clinical trial specifically on this species identifiable through peer-reviewed databases — may itself be an understatement of the evidence gap.

The evidence base for health effects attributed to P. tomentosa as a dietary supplement ingredient is therefore currently: absent at the clinical (human) level, absent at the animal study level for this specific species, and unconfirmed even at the in vitro level by any independently verifiable, peer-reviewed publication.

Evidence from the Broader Paullinia Genus

The following summarizes scientifically documented evidence for the most studied Paullinia species, to provide genus-level context. None of this evidence can be directly attributed to P. tomentosa without species-specific data.

Central Nervous System Stimulation and Cognitive Effects (P. cupana)

The stimulant effects of purine alkaloids are related to their ability to inhibit cAMP phosphodiesterases and adenosine receptors, promoting, among others, an increase in mental alertness, physical performance, and reduction of fatigue. For guarana (P. cupana), guarana is a Brazilian seed extract that contains caffeine and other bioactive compounds that may have psychoactive effects. In one double-blind, crossover study assessing the acute effects of guarana compared to a low dose of caffeine on cognitive and mood parameters, twenty participants ingested capsules containing either 100 mg caffeine, 500 mg guarana containing 130 mg caffeine, or placebo. Cognitive tests were performed at baseline and 60 minutes after ingestion; the response time for the cognitive tests and heart rate variability were unaffected by treatment, although 2N-Back performance was overall faster across time. This represents a small, single-session crossover study with limited power, and findings were largely non-significant between active conditions.

Antioxidant and Anti-Aging Properties (P. cupana, Preclinical)

When tested in the model organism Caenorhabditis elegans, water extract from roasted guarana seeds enhanced resistance against oxidative stress, extended lifespan, and attenuated aging markers such as muscle function decline and polyQ40 aggregation. These experiments demonstrated that guarana extracts can act as a powerful antioxidant in vivo, and that biological activities of guarana go beyond extensively reported CNS stimulation. These findings are limited to an invertebrate model system and cannot be extrapolated to human health outcomes.

Anti-Inflammatory and Analgesic Effects (P. pinnata, Preclinical)

For Paullinia pinnata, research has focused on the search for new natural drugs with antigouty effects, combining anti-inflammatory, analgesic, and antioxidant properties. P. pinnata is a creeper plant widely distributed in the west and center regions of Cameroon, empirically used for the treatment of infection and painful and inflammatory diseases. Previous pharmacological studies demonstrated antimicrobial activities and protective effects against CCl4-induced hepatic damage and oxidative stress. These are preclinical (animal or in vitro) findings and have not been validated in human clinical trials.

Antimicrobial Properties (P. pinnata, Preclinical)

Paullinia pinnata is an African woody vine widely used in traditional medicine for the treatment of human malaria, erectile dysfunction, and bacterial infections. A phytochemical investigation of its methanol leaf and stem extracts led to the isolation of seven compounds which were evaluated for their antimicrobial properties. Antimicrobial activity was demonstrated in vitro using the broth micro-dilution technique. These are laboratory findings without clinical validation.

Body Systems and Health Areas Associated with the Supplement Ingredient

Commercial positioning of Paullinia tomentosa as a dietary supplement ingredient generally associates it with the following body systems. Where peer-reviewed evidence exists for this or closely related species, it is noted; where claims rest solely on commercial attribution or unverified inference, that is stated explicitly.

• Central nervous system / Energy metabolism: Claims of stimulant and fatigue-reducing activity mirror those of P. cupana. For P. cupana, the seeds are popular in South America due to their stimulant activity on the central nervous system, and are extensively used in the Brazilian beverage industry. Rich in purine alkaloids, markedly caffeine, they are used as additives in energy drinks. Whether P. tomentosa exerts any analogous CNS activity is unconfirmed; the Weckerle et al. (2003) chemotaxonomic screen did not detect purine alkaloids in this species.
• Antioxidant defense / Cellular health: Genus-level evidence suggests that Paullinia species contain phenolic compounds with antioxidant capacity, as demonstrated for P. cupana (in vivo, invertebrate model). No such data exist for P. tomentosa specifically.
• Gastrointestinal system: P. cupana has historically been used as an astringent; its high tannin content underpins this traditional application. Commercial claims for P. tomentosa as a digestive aid are not corroborated by peer-reviewed species-specific evidence.
• Immune support / Anti-inflammatory: Preclinical evidence for anti-inflammatory activity exists for genus congeners (P. pinnata), but no species-specific data for P. tomentosa have been identified in peer-reviewed sources.
• Antimicrobial: In vitro antimicrobial activity has been demonstrated for P. pinnata isolated compounds. Again, no parallel data for P. tomentosa have been identified in the peer-reviewed literature.

Dosage Forms and Reported Dosages

Paullinia tomentosa Jacq. does not appear in any government pharmacopoeia, regulatory monograph (WHO, ESCOP, Commission E, EMA, USP, European Pharmacopoeia), or evidence-based database monograph (such as NCCIH or NIH ODS) that would establish standardized or recommended dosages. No peer-reviewed clinical trials involving human subjects and specifying doses of P. tomentosa were identified through systematic literature searches.

For comparison, dosages reported in clinical research on the closely related Paullinia cupana (guarana) — the best-studied congener — include the use of 500 mg guarana containing 130 mg caffeine in a double-blind, crossover human study. Paullinia cupana extract (from seed) is approved in the United States as a food additive and is considered a dietary supplement; it is also listed in the official Brazilian Pharmacopoeia. No analogous regulatory status has been identified for P. tomentosa.

In the absence of peer-reviewed dosage data for P. tomentosa, no dosage can be stated for this article consistent with the sourcing requirements applied here.

Safety Considerations and Potential Interactions

No peer-reviewed toxicological or clinical safety studies specific to Paullinia tomentosa Jacq. were identified. In the absence of such data, safety cannot be characterized for this species based on authoritative sources.

The following points are drawn from verifiable sources relating to the genus or to potential pharmacological class effects, and are presented as contextually relevant rather than as direct evidence for P. tomentosa:

• Caffeine-related risks (genus-level, applicable only if purine alkaloids are confirmed present): The use of multiple herbal products containing guarana and other sources of caffeine can result in caffeine toxicity. Since the Weckerle et al. (2003) chemotaxonomic screen of 34 Paullinia species did not detect purine alkaloids in P. tomentosa, caffeine-class risks may not be applicable, but this cannot be confirmed without species-specific validated phytochemical analysis of commercially sourced material.
• Herb-drug interactions (P. cupana data only): Peer-reviewed research on guarana has identified the potential for pharmacokinetic interactions. The Committee on Herbal Medicinal Products (HMPC) of the European Medicines Agency has launched a call to encourage the submission of scientific data on Paullinia cupana (guarana) in order to prepare the corresponding herbal monograph, reflecting regulatory concern about the widespread use of caffeine-containing Paullinia preparations. Whether analogous interactions apply to P. tomentosa is unknown.
• Hepatotoxicity (P. cupana data only): In conventional doses, guarana has few side effects and has not been linked to episodes of liver injury or jaundice. This applies specifically to P. cupana, not to P. tomentosa.
• Fish toxicity in the genus: Several Paullinia species — notably P. pinnata and species with toxic sap — have historically been exploited as fish poisons. The sap of some species, notably P. cururu, is highly toxic and is used as an arrow poison by Native American tribes in South America. This ichthyotoxic potential within the genus highlights that not all Paullinia species are pharmacologically benign, and that species-specific safety evaluation is essential.

Regulatory and Commercial Status

Paullinia tomentosa Jacq. does not appear in the NIH Office of Dietary Supplements database, the NCCIH herb fact sheets, the WHO monograph series on selected medicinal plants, the ESCOP monograph series, the German Commission E monographs, the European Pharmacopoeia, or the United States Pharmacopeia as an ingredient with a recognized monograph or regulatory review. It does not appear in the EMA list of assessed herbal medicinal product ingredients. Its presence in the commercial dietary supplement marketplace, where it is listed as an ingredient in at least some products, therefore occurs in a regulatory environment where it has not been subject to the formal evidence review processes applied to better-characterized botanical ingredients.

Critical Assessment of the Evidence Base

The following summarizes the evidentiary status of Paullinia tomentosa as a dietary supplement ingredient, applying the hierarchy of evidence required by rigorous assessment:

• Human clinical trials: None identified in peer-reviewed literature for P. tomentosa specifically.
• Animal studies: None identified in peer-reviewed literature for P. tomentosa specifically.
• In vitro / laboratory studies: None identified in peer-reviewed literature for P. tomentosa specifically.
• Phytochemical characterization: Not established in peer-reviewed literature for P. tomentosa specifically. The most relevant genus-level chemotaxonomic study (Weckerle et al., 2003) screened this species and did not detect purine alkaloids, contrary to commercial claims of caffeine content.
• Ethnobotanical documentation: Not confirmed in peer-reviewed ethnopharmacological literature for P. tomentosa specifically as a named subject of investigation.
• Pharmacopeial / monograph status: Absent in all assessed authoritative compendia.

Claims found in commercial supplement ingredient databases attributing stimulant, energy-enhancing, antioxidant, antimicrobial, and anti-inflammatory activities to Paullinia tomentosa appear to rest on inference from the better-studied congener P. cupana (guarana) rather than on species-specific evidence. Among the few purine alkaloid-containing genera consumed as stimulants, Paullinia is the least investigated with respect to both chemotaxonomy and within-the-plant allocation of caffeine and its allies; this applies with even greater force to P. tomentosa, for which the available peer-reviewed genus-level screening did not confirm purine alkaloid content.

References

• GBIF Backbone Taxonomy — Paullinia tomentosa Jacq. (Species Entry)
• NCBI Taxonomy — Paullinia tomentosa (Taxonomy ID: 1823681)
• Weckerle CS, Stutz MA, Baumann TW (2003). Purine alkaloids in Paullinia. Phytochemistry 64: 735–742. PubMed PMID: 13679096
• Phylogeny of Paullinia L. (Paullinieae: Sapindaceae), a diverse genus of lianas with rapid fruit evolution. bioRxiv preprint.
• Wikipedia — Paullinia (genus overview and species list)
• Wikipedia — Paullinia pinnata
• Antimicrobial steroidal saponin and oleanane-type triterpenoid saponins from Paullinia pinnata. PMC4192449
• Aqueous and Methanol Extracts of Paullinia pinnata Improve Monosodium Urate-Induced Gouty Arthritis in Rat. PMC6915157
• Guarana — LiverTox® — NCBI Bookshelf (NIH). NBK589113
• Guarana — PubMed entry (LiverTox reference). PMID 36753599
• Anti-Aging and Antioxidant Potential of Paullinia cupana var. sorbilis: Findings in Caenorhabditis elegans. PMC5622396
• Effects of Acute Guarana (Paullinia cupana) Ingestion on Mental Performance and Vagal Modulation Compared to a Low Dose of Caffeine. PubMed PMID 38931247
• Herb-Drug Interaction of Paullinia cupana (Guarana) Seed Extract on the Pharmacokinetics of Amiodarone in Rats. PMC3523151
• Paullinia cupana Kunth (Sapindaceae): A review of its ethnopharmacology, phytochemistry and pharmacology. ResearchGate / Journal of Medicinal Plants Research
• Purine alkaloids in Paullinia — ResearchGate full text (Weckerle et al., 2003)